REGENERON PHARMACEUTICALS (REGN)
US75886F1075 - Common Stock
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of...
2 Small-Cap Growth Stocks With Room To Run
These two small-cap growth stocks could be ready to run.
Noteworthy Tuesday Option Activity: NUE, PNC, REGN
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic...
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise.
RSI Alert: Regeneron Pharmaceuticals (REGN) Now Oversold
Nasdaq 100 Movers: FAST, TEAM
S&P 500 Analyst Moves: REGN
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)...
Should You Sell This Stock Following a Regulatory Roadblock?
It's not the first such obstacle this high-performing drugmaker has faced.
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter...
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.
Regeneron Provides Update on Biologics License Application for Odronextamab
Regeneron Provides Update on Biologics License Application for Odronextamab
TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug...
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend.